Similar to the other two potential ADC candidates, CD138 shows a stable gene expression over all stages of cervical cancer with an intermediate strength of gene expression as compared to TROP2 and CEACAM5 (Figure 4A). This evidence concerns the gene CEACAM5 and cervical cancer.